Intuitive Surgical stands out from other large cap healthcare companies as a high-growth company and a pure play in very attractive segment of the industry. The seemingly elevated earnings multiple is a cause of concern to many, but it is justified once we account for the overall quality of the business model. International and procedure expansion of ISRG platforms make the highly profitable bu...
Intuitive Surgical has become a more attractive opportunity after a 28% stock decline, prompting an upgrade from Hold to Buy. ISRG operates in a high-growth surgical robotics market, which could nearly triple by 2033, supporting long-term bullishness. Despite a premium valuation, ISRG's consistent top and bottom-line growth and management execution justify its price.
Current Chief Commercial and Marketing Officer Henry Charlton to become SVP of Global Business Operations Current Chief Commercial and Marketing Officer Henry Charlton to become SVP of Global Business Operations
Latest innovations include enhanced telecollaboration capabilities, extended uses for Force Feedback technology, and advancements in product and instrument reliability and security Latest innovations include enhanced telecollaboration capabilities, extended uses for Force Feedback technology, and advancements in product and instrument reliability and security
Intuitive Surgical's NASDAQ: ISRG primary headwinds are its high valuation and slowing growth. The combination has weighed on price action since early 2025 and is unlikely to go away soon.
The key takeaway from Intuitive Surgical's (ISRG) Q1 2026 results is the implementation of a fundamental “Platform Refresh Wall.” In addition to the $2.50 EPS exceeding expectations and a revenue growth of 23%, this cycle reshapes the competitive environment for the upcoming decade.
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.